Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPuerta de Hierro University Hospital
About this trial
The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.
The main question it aims to answer is whether there is a difference in natriuresis 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2).
Eligibility criteria
Qualifiers
Patients admitted for acute heart failure and ≥ 1 clinical sign of volume overload (edema, ascites, or pleural effusion).
NTproBNP levels >1000 pg/mL or BNP >250 ng/mL on admission.
Under treatment with furosemide and iSGLT2 according to European guidelines and indication of association of another diuretic due to residual congestion data defined by ADVOR SCORE>1.
Disqualifiers
Systolic blood pressure <90 mmHg or mean arterial pressure < 65 mmHg.
Maintenance treatment with acetazolamide/ Treatment with acetazolamide in the month prior to inclusion in the study.
Anticipated need for intravenous inotropes, vasopressors or nitroprusside during the study.
Contraindication to ISGLT2.
Trial design
Treatments tested in this trial
- Acetazolamide 500mg
Treatment groups
64 Participants
are divided into 1 treatment groupSponsors and collaborators
Puerta de Hierro University Hospital
Lead sponsor
Hospital Clinic of Barcelona
Collaborator
Hospital Central de la Defensa Gómez Ulla
Collaborator
Hospital Vall d'Hebron
Collaborator
Hospital Universitario Ramon y Cajal
Collaborator
University Hospital of Girona Dr. Josep Trueta
Collaborator
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Collaborator
Source ClinicalTrials.gov